Breast cancer is the most commonly diagnosed cancer among women. Therapeutic treatments for breast cancer generally include surgery, chemotherapy, radiotherapy, endocrinotherapy and molecular targeted therapy. With the development of molecular biology, immunology and pharmacogenomics, immunotherapy becomes a promising new field in breast cancer therapies. In this review, we discussed recent progress in breast cancer immunotherapy, including cancer vaccines, bispecific antibodies, and immune checkpoint inhibitors. Several additional immunotherapy modalities in early stages of development are also highlighted. It is believed that these new immunotherapeutic strategies will ultimately change the current status of breast cancer therapies.

No abstract

No abstract

Colorectal cancer (CRC) represents the third most common type of cancer in developed countries and one of the leading causes of cancer deaths worldwide. Personalized management of CRC has gained increasing attention since there are large inter-individual variations in the prognosis and response to drugs used to treat CRC owing to molecular heterogeneity. Approximately 15% of CRCs are caused by deficient mismatch repair (dMMR) characterized by microsatellite instability (MSI) phenotype. The present review is aimed at highlighting the role of MMR status in informing prognosis and personalized treatment of CRC including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy to guide the individualized therapy of CRC.

Bi-self-doped BiVO (Bi-BVO) nanotubes with p-n homojunctions are fabricated via an oxygen-induced strategy. Calcinating the as-spun fibers with abundant oxygen plays a pivotal role in achieving Bi self-doping. Density functional theory calculations and experimental results indicate that Bi self-doping can narrow the band gap of BiVO, which contributes to enhancing light harvesting. Moreover, Bi self-doping endows BiVO with n- and p-type semiconductor characteristics simultaneously, resulting in the construction of p-n homojunctions for retarding rapid electron-hole recombination. Benefiting from these favorable properties, Bi-BVO exhibits a superior photocatalytic performance in contrast to that of pristine BiVO. Furthermore, this is the first report describing the achievement of p-n homojunctions through self-doping, which gives full play to the advantages of self-doping.

π Backdonation is the core process to break through the kinetically complex and energetic hurdle for catalyzing effectively the NH 3 synthesis but only occurs on certain transition metals with empty and filled d orbitals. Herein, mimicking π backdonation enables MOF-76(Ce) materials to convert N 2 /NH 3 effectively. Note that, by virtue of the intrinsic mechanism of ligand-to-metal charge transfer, metal cerium species in MOF-76(Ce) serve as an electron sink for accumulating the photogenerated electrons. Taken together, experimental and theoretical analyses reveal that such metal cerium species with coordination unsaturated state (Ce-CUS) on a MOF-76(Ce) nanorod surface can also provide unoccupied and occupied 4f orbitals to accept from and then donate electrons back to nitrogen molecules. Remarkably, it shows outstanding photocatalytic nitrogen reduction performance with high average NH 3 yield (34 μmol g −1 h −1 ) under ambient conditions. This work provides fresh insights into rational designing and engineering highly active catalysts with rare earth elements.

HMGB3 overexpression has been reported in a variety of human cancers. However, the role of HMGB3 in human non-small cell lung cancer (NSCLC) remains unclear. In this study, the HMGB3 expression was examined at mRNA and protein levels by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry in NSCLC tissues and adjacent non-cancerous tissues. Statistical analyses were applied to test the associations between HMGB3 expression, clinicopathologic factors, and prognosis. Western blotting and qRT-PCR showed that the expression levels of HMGB3 mRNA and protein were both significantly higher in NSCLC tissues than those in non-cancerous tissues. Immunohistochemistry analysis showed that HMGB3 expression was significantly correlated with tumor grade, tumor size, clinical stage, and lymph node metastases. The results of Kaplan-Meier analysis indicated that a high expression level of HMGB3 resulted in a significantly poor prognosis of NSCLC patients. Importantly, multivariate analysis showed that high HMGB3 expression was an independent prognostic factor for NSCLC patients. In sum, our data suggest that HMGB3 plays an important role in NSCLC progression, and that overexpression of HMGB3 in tumor tissues could be used as a potential prognostic marker for patients with NSCLC.

No abstract